Abstract: Described herein are novel preparations of functionalized erythroid cells and related compositions, reagents, and methods for use in human pharmaceutical and veterinary applications.

Abstract: The present disclosure provides customizable enucleated erythroid cells or enucleated cells that can be engineered to include, on their surface, a loadable exogenous antigen-presenting polypeptide, wherein the loadable exogenous antigen-presenting polypeptide comprises one or more amino acid substitutions. In some embodiments, the one or more amino acid substitutions stabilize the loadable exogenous antigen-presenting polypeptide on the cell surface. In some embodiments, the loadable exogenous antigen-presenting polypeptide is stabilized on the cell surface in the absence of a polypeptide bound to the loadable exogenous antigen-presenting polypeptide. In some embodiments, the loadable exogenous antigen-presenting polypeptide comprises an exogenous displaceable polypeptide bound to the loadable exogenous antigen-presenting polypeptide. In some embodiments, the loadable exogenous antigen-presenting polypeptide is stabilized on the cell surface upon release of the displaceable polypeptide.

Abstract: The present disclosure relates to artificial antigen presenting cells (aAPCs), in particular engineered erythroid cells and enucleated cells (e.g., enucleated erythroid cells and platelets), that are engineered to include exogenous-antigen presenting polypeptides comprising either HLA-E or HLA-G polypeptides, which may be used to activate or suppress certain immune cells.

Abstract: In some implementations, a server device can generate configuration data for an application based on user engagement segments associated with a user of the application. For example, a server device can receive information identifying user engagement segments associated with a particular user. When the server device receives a request for configuration data for the application that identifies the particular user, the server device can obtain the engagement segment identifiers associated with the particular user. The server device can use the engagement segment identifiers to obtain segment configuration data for each engagement segment identifier, combine the segment configuration data into a combined configuration, and send the combined configuration to the application on the user device. The application can then determine what content to present and how to present the content on the user device based on the combined configuration data.

Abstract: The present disclosure relates to artificial antigen presenting cells (aAPCs), in particular engineered erythroid cells and enucleated cells (e.g. enucleated erythroid cells and platelets), that are engineered to activate or suppress T cells.